Roche’s phase III FENtrepid study of fenebrutinib meets its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with PPMS ...

Alteplase, a “clot-buster” medication used to treat ischemic stroke, acute myocardial infarctions, and acute pulmonary ...

The former CFO who orchestrated Nobel Laureates, revolutionized NFL safety, and proved your outsider status is your greatest ...

The Scottish Medicines Consortium has rejected donanemab for early Alzheimer’s disease, citing inadequate clinical and economic evidence.

Tolebrutinib failed to lower disability progression risk in primary progressive MS in a Phase 3 trial, with data shown at ...

Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...

Century Therapeutics (IPSC) aims at a durable “once-and-done” Type 1 diabetes cure with hypoimmune iPSC beta cells; runway to 2029—click here to read now.

Better alignment with Mediterranean diet patterns is associated with reduced risks for functional worsening in individuals with early MS.

The fix to micromanaging is clearer decision rights, faster closure and visible accountability, so leaders can lead and the ...

The high-dose regimen of SPINRAZA (nusinersen) is approved in the European Union and Japan. The high-dose regimen is under review with the United States Food and Drug Administration (FDA) and has a ...

The E-Commerce & Digital Marketing Association (ECDMA) announces the admission of Aleksei Sovetkin to its Senior Member tier, ...

The results reinforce the need for individualized, biology-driven therapeutic decisions in patients with MS. SAN DIEGO – Older patients with MS had increased neuroaxonal and astroglial injury ...